Modality
Gene Editing
MOA
CDK2i
Target
IL-13
Pathway
Hedgehog
PsAPTSDCLL
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
Feb 2017
→ Nov 2029
Phase 3Current
NCT05895750
2,221 pts·PTSD
2025-04→2029-11·Terminated
NCT05671728
630 pts·CLL
2017-02→2027-10·Not yet recruiting
NCT04329444
2,383 pts·CLL
2022-11→2027-07·Recruiting
+1 more trial
7,614 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (5)
2025-09-206mo agoBTD· PTSD
2027-07-111.3y awayPh3 Readout· CLL
2027-10-261.6y awayPh3 Readout· CLL
2029-07-113.3y awayPh3 Readout· PsA
2029-11-143.6y awayPh3 Readout· PTSD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Not yet…
P3
Recruit…
P3
Recruit…
P3
Termina…
Catalysts
BTD
2025-09-20 · 6mo ago
PTSD
Ph3 Readout
2027-07-11 · 1.3y away
CLL
Ph3 Readout
2027-10-26 · 1.6y away
CLL
Ph3 Readout
2029-07-11 · 3.3y away
PsA
Ph3 Readout
2029-11-14 · 3.6y away
PTSD
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05895750 | Phase 3 | PTSD | Terminated | 2221 | MRD |
| NCT05671728 | Phase 3 | CLL | Not yet recr... | 630 | EDSS |
| NCT04329444 | Phase 3 | CLL | Recruiting | 2383 | CfB |
| NCT05032056 | Phase 3 | PsA | Recruiting | 2380 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |